XOMA royalty-2c.png
XOMA Initiates XOMA 358 Proof-of-Concept Study in Patients with Hypoglycemia Post Gastric Bypass Surgery
27 avr. 2016 09h00 HE | XOMA Corporation
BERKELEY, Calif., April 27, 2016 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, announced today it has initiated its...
InSpark Technologies
InSpark Technologies Appoints Diabetes Experts to Inaugural Thought Leadership Council
26 avr. 2016 08h00 HE | InSpark Technologies
CHARLOTTESVILLE, Va., April 26, 2016 (GLOBE NEWSWIRE) -- InSpark Technologies, a leader in diabetes advanced pattern recognition technology, today announced the formation of its Thought Leadership...
Hypo Risk Indicator graphic.jpg
New Vigilant™ Diabetes Management Companion Launched in U.S. That Alerts Users to Risk of Severe Hypoglycemia in Next 24 Hours
26 avr. 2016 08h00 HE | InSpark Technologies
CHARLOTTESVILLE, Va., April 26, 2016 (GLOBE NEWSWIRE) -- InSpark Technologies, Inc., a leader in diabetes pattern recognition technology, today announced that VigilantTM1 is now available for...
XOMA royalty-2c.png
XOMA Presented First Data from Novel Antibody Fragment to Address Severe Acute Hypoglycemia at the ENDO Meeting
04 avr. 2016 09h00 HE | XOMA Corporation
BERKELEY, Calif., April 04, 2016 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, announced the presentation of data from...
XOMA royalty-2c.png
XOMA Reports Fourth Quarter and Full-Year 2015 Financial Results
09 mars 2016 16h01 HE | XOMA Corporation
BERKELEY, Calif., March 09, 2016 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, today reported the completion of its...
xeris_logo-1.png
Xeris Pharmaceuticals, Inc. to Present G-Pen Human Factors Study Results at 2016 ATTD Meeting
04 févr. 2016 10h22 HE | Xeris Pharmaceuticals, Inc.
Austin, TX, Feb. 04, 2016 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. (“Xeris”) will present data from a human factors study with its G-PenTM glucagon auto-injector during the 9th International...
InSpark Technologies
InSpark Technologies Presents Study Results Supporting the Utility of Its Hypo Risk Indicator at the Diabetes Technology Meeting
22 oct. 2015 08h00 HE | InSpark Technologies
BETHESDA, Md., Oct. 22, 2015 (GLOBE NEWSWIRE) -- InSpark Technologies, Inc., a leader in diabetes pattern recognition technology, has announced it is presenting a poster at the Diabetes Technology...
xeris_logo-1.png
Xeris Pharmaceuticals Presents Non-Aqueous Glucagon Stability Data at the American Diabetes Association 73nd Scientific Sessions
21 juin 2013 10h00 HE | Xeris Pharmaceuticals, Inc.
Austin, TX, June 21, 2013 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. ("Xeris") announces today that it is presenting at the American Diabetes Association 73nd Scientific Sessions in Chicago, IL...
xeris_logo-1.png
Xeris Pharmaceuticals Awarded Phase II Funding of NIH Fast -Track SBIR Grant to Advance Glucagon for the Artificial Pancreas
17 avr. 2013 11h39 HE | Xeris Pharmaceuticals, Inc.
Austin, TX, April 17, 2013 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. ("Xeris"), an Austin-based, pharmaceutical company developing patient-friendly injectable treatments for diabetes and other...